MILESTONE SCIENTIFIC INC. 8-K

What Happened
Milestone Scientific Inc. (MLSS) filed an 8-K (July 29, 2026) disclosing that three company directors—Benedetta Casamento, Dr. Didier Demesmin and Neal Goldman—submitted notices on July 24, 2026 electing to convert the remaining outstanding balances on their amended and restated promissory notes (the "Convertible Bridge Notes") into shares of common stock. The Convertible Bridge Notes were originally issued in aggregate for $800,000 and were partially converted in connection with a private placement that closed April 20, 2026. No shares have been issued yet; conversions will become effective only when the fair value of the common stock is at least $0.50 per share and the converting director is permitted to trade under the company’s Insider Trading Policy.

Key Details

• Conversion notices received: July 24, 2026; 8-K filed July 29, 2026.
• Remaining principal covered by notices:
  • Benedetta Casamento: $116,495.47
  • Dr. Didier Demesmin: $58,247.73
  • Neal Goldman: $291,238.66
• Original aggregate principal of Convertible Bridge Notes: $800,000 (partially converted April 20, 2026).
• Conversion condition: becomes effective only when the Fair Value of MLSS common stock is not less than $0.50 per share and insider trading rules permit.

Why It Matters
If triggered, these conversions would replace debt owed under the notes with newly issued common shares, reducing the company’s outstanding note obligations to these directors and increasing the share count (dilution). Timing and impact depend on the company’s stock reaching the $0.50 fair value threshold and compliance with insider trading restrictions; as of the 8-K date, no conversions had been completed. Investors should watch for future disclosures showing the stock’s fair value crossing the trigger point or any actual issuance of shares.